Skip to Main Content

Paper Details

Limited extent and consequences of pancreatic SARS-CoV-2 infection.
Cell Rep
31
2022
COVID-, COVID-19, SARS-CoV, SARS-CoV-2, SARS-CoV-2 entry receptor ACE2, coronavirus disease 2019, diabetes, human, in vitro SARS-CoV-2-infected human pancreatic islets, infected subsets, islet, pancreatic cell types, severe acute respiratory syndrome coronavirus
Author NameAffiliation
Verena van der HeidePrecision Immunology Institute, Icahn School of Medicine at Mount Sinai
Phillip CohenIcahn School of Medicine at Mount Sinai
Raveen RathnasingheIcahn School of Medicine at Mount Sinai, USA Global Health and Emerging Pathogens Institute
Teresa AydilloIcahn School of Medicine at Mount Sinai, USA Global Health and Emerging Pathogens Institute
Adeeb RahmanIcahn School of Medicine at Mount Sinai
Seunghee Kim-SchulzePrecision Immunology Institute, Icahn School of Medicine at Mount Sinai
Seunghee Kim-SchulzePrecision Immunology Institute, Icahn School of Medicine at Mount Sinai
Randy A AlbrechtIcahn School of Medicine at Mount Sinai, USA Global Health and Emerging Pathogens Institute
Adolfo Garc??a-SastreIcahn School of Medicine at Mount Sinai, USA Global Health and Emerging Pathogens Institute, USA The Tisch Cancer Institute
Michael SchotsaertIcahn School of Medicine at Mount Sinai, USA Global Health and Emerging Pathogens Institute
Dirk HomannPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, USA Diabetes Obesity & Metabolism Institute
  • 1 - 11

Datasets

Release 1.2